Literature DB >> 24931916

Lymphatic and blood vasculature in primary cutaneous melanomas of the scalp and neck.

Sandro Pasquali1, Maria Cristina Montesco2, Chiara Ginanneschi3, Gianna Baroni4, Clelia Miracco5, Carmelo Urso3, Fabio Mele6, Anna Rita Lombardi7, Pietro Quaglino8, Laura Cattaneo9, Stefania Staibano10, Gerardo Botti11, Paolo Visca12, Marina Zannoni13, Giuseppe Soda14, Barbara Corti15, Luca Pilloni16, Luca Anselmi17, Amelia Lissia18, Margherita Vannucchi4, Cristina Manieli19, Daniela Massi4.   

Abstract

BACKGROUND: Scalp/neck melanomas have a poor prognosis, possibly because of a rich vascular supply that prompts tumor cells' dissemination.
METHODS: We compared the accuracy of immunohistochemical (IHC) staining with morphology for the identification of lymphovascular invasion in 156 scalp/neck melanomas. We then analyzed the association of vessel invasion and density with pathological features and survival.
RESULTS: IHC-detected lymphatic vessel invasion (LVI) and blood vessel invasion (BVI) were identified in 34.6% and 13.5% of cases, respectively. IHC increased the LVI/BVI detection compared to morphology (40.4% vs 16.6%; p < .001). The degree of peritumoral and intratumoral blood vessel density (BVD) was greater than lymphatic vessel density (LVD). Ulceration was the only factor independently associated with intratumoral (p = .029) and peritumoral (p = .047) BVD. Tumor thickness was the only independent predictor of survival (p = .002).
CONCLUSION: IHC allows accurate assessment of lymphovascular invasion in scalp/neck melanomas. In these tumors, we observed a high incidence of BVI, which deserves further investigations.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  blood vessel density; blood vessel invasion; cutaneous melanoma; head and neck; lymphatic vessel density; lymphatic vessels invasion; scalp and neck

Mesh:

Year:  2014        PMID: 24931916     DOI: 10.1002/hed.23801

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  5 in total

1.  Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis.

Authors:  Laura J Gardner; Morgan Ward; Robert H I Andtbacka; Kenneth M Boucher; Glen M Bowen; Tawnya L Bowles; Adam L Cohen; Kenneth Grossmann; Ying J Hitchcock; Sheri L Holmen; John Hyngstrom; Hung Khong; Martin McMahon; Marcus M Monroe; Carolyn B Ross; Gita Suneja; David Wada; Douglas Grossman
Journal:  Melanoma Res       Date:  2017-10       Impact factor: 3.599

2.  Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma.

Authors:  Emily Z Keung; Jeffrey E Gershenwald
Journal:  J Natl Cancer Inst       Date:  2020-09-01       Impact factor: 13.506

3.  Curcumin analog DM-1 in monotherapy or combinatory treatment with dacarbazine as a strategy to inhibit in vivo melanoma progression.

Authors:  Fernanda Faião-Flores; José Agustín Quincoces Suarez; Andréa Costa Fruet; Silvya Stuchi Maria-Engler; Paulo Celso Pardi; Durvanei Augusto Maria
Journal:  PLoS One       Date:  2015-03-05       Impact factor: 3.240

4.  A cross-sectional study of clinical, dermoscopic, histopathological, and molecular patterns of scalp melanoma in patients with or without androgenetic alopecia.

Authors:  Ana Carolina Porto; Tatiana Pinto Blumetti; Vinícius Fernando Calsavara; Giovana Tardin Torrezan; Cláudia Alessandra Andrade de Paula; Rute Lellis; João Pedreira Duprat Neto; Dirce Maria Carraro; J Casagrande Tavoloni Braga
Journal:  Sci Rep       Date:  2022-09-05       Impact factor: 4.996

5.  Primary cutaneous melanoma of the scalp: Patterns of clinical, histological and epidemiological characteristics in Brazil.

Authors:  Ana Carolina Porto; Tatiana Pinto Blumetti; Ivan Dunshee de Abranches Oliveira Santos Filho; Vinicius Fernando Calsavara; João Pedreira Duprat Neto; Juliana Casagrande Tavoloni Braga
Journal:  PLoS One       Date:  2020-10-23       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.